<DOC>
	<DOCNO>NCT00309569</DOCNO>
	<brief_summary>Primarily , clinical investigation compare overall survival recurrence-free survival patient hormone receptor-negative breast cancer treat pre- postoperative chemotherapy vs. conventional postoperative treatment .</brief_summary>
	<brief_title>Randomized Study Comparing Pre- Postoperative Vs . Conventional Adjuvant Treatment Receptor-Negative Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Patients bioptically verify breast cancer Estrogen receptornegative status Age : &lt; 70 year WHO Performance Status &lt; 2 Laboratory parameter 1. hematopoiesis : &gt; 3500/l leukocyte , &gt; 100,000/l thrombocyte 2. renal function : creatinin &lt; 1.5mg % 3. hepatic function : GOT  2.5 x UNL 4. bilirubin : &lt; 2.0 mg % 5. metabolic parameter : Na , Ca , K normal range &lt; /= 4 week interval since surgery Informed consent Patients locally inoperable cancer , M1 Other preoperative tumorspecific radiotherapy , chemotherapy endocrine treatment Pregnancy lactation General contraindication cytostatic treatment T4 cancer ; inflammatory disease , simultaneous sequential bilateral breast cancer Lacking compliance understanding disease Serious concomitant disease Second carcinoma status post second carcinoma ( except treat squamous cell carcinoma skin cervical carcinoma situ )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 1999</verification_date>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Fluorouracil</keyword>
	<keyword>Epirubicine</keyword>
	<keyword>Breast Cancer</keyword>
</DOC>